1-20 of 72
Peter Johnson
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Creation of a Multistate Model to Improve Prognostication across the Disease Course in Advanced Stage Classic Hodgkin Lymphoma (cHL): A Report from the Holistic Consortium

Angie Mae Rodday, Susan K. Parsons, Zhu J Cui, Qingyan Xiang, Nicholas Counsell, Sara Rossetti, Jenica N Upshaw, Annalynn M Williams, Amy A Kirkwood, Hongli Li, James R. Cerhan, Massimo Federico, Jonathan W. Friedberg, Andrea Gallamini, Eliza A. Hawkes, David Hodgson, Martin Hutchings, Peter Johnson, Brian K. Link, Eric Mou, John Radford, Kerry J. Savage, Deborah M. Stephens, Pier Luigi Zinzani, Matthew J. Maurer, Andrew M Evens
Journal: Blood
Blood (2024) 144 (Supplement 1): 567.
https://doi.org/10.1182/blood-2024-207439
Published: 2024
Journal Articles

PET-Based Prognostic Stratification in Primary Mediastinal B-Cell Lymphoma Using the SUV≥4 Segmentation Threshold: A Comparative Analysis of Contouring Methods in the IELSG37 Trial Cohort

Luca Ceriani, Lisa Milan, Maria Cristina Pirosa, Alice Di Rocco, Teresa Ruberto, Luciano Cascione, Peter Johnson, Andrew J. Davies, Maurizio Martelli, Emanuele Zucca
Journal: Blood
Blood (2024) 144 (Supplement 1): 1712.
https://doi.org/10.1182/blood-2024-206784
Published: 2024
Journal Articles

Involved Field Radiotherapy Versus No Further Treatment in Patients with Newly Diagnosed Stage 1A or 2A Hodgkin Lymphoma and a ‘Negative’ PET Scan after 3 Cycles ABVD. Survival and Cause of Death after a Median of 16 Years Follow-up in the UK RAPID Trial

John Radford, Joanna Williams, Darren Edwards, Ruth Pettengell, Peter Johnson, Peter Hoskin, Timothy Illidge, Nicholas Counsell
Journal: Blood
Blood (2024) 144 (Supplement 1): 457.
https://doi.org/10.1182/blood-2024-200662
Published: 2024
Journal Articles

Development and Validation of the Early-Stage Hodgkin Lymphoma (HL) International Prognostication Index (E-HIPI): A Report from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium

Andrew M Evens, Angie Mae Rodday, Matthew J. Maurer, Ranjana H. Advani, Marc Andre, Andrea Gallamini, Annette E. Hay, David Hodgson, Richard T. Hoppe, Martin Hutchings, Peter Johnson, Brian K. Link, Stephen Opat, John M. Raemaekers, Jenica Upshaw, Qingyan Xiang, Nicholas Counsell, Susan K Parsons, John Radford
Journal: Blood
Blood (2023) 142 (Supplement 1): 3058.
https://doi.org/10.1182/blood-2023-173320
Published: 2023
Journal Articles

Bleomycin Affects Lung Function for at Least 5 Years after Treatment for Hodgkin Lymphoma - Data from the International, Randomised Phase 3 Rathl Trial

Elizabeth H Phillips, Amy A Kirkwood, Christina Hague, Jorgen Vestbo, Massimo Federico, Francesco D'Amore, Alexander Fossa, Judith Trotman, Leanne Berkahn, Daniel L. Molin, Stefano Luminari, Sally F Barrington, Peter Johnson, John Radford
Journal: Blood
Blood (2023) 142 (Supplement 1): 612.
https://doi.org/10.1182/blood-2023-185818
Published: 2023
Journal Articles

Identification of Risk Categories from the Advanced-Stage Hodgkin International Prognostic Index (A-HIPI) Model: A Detailed Analysis from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium

Matthew J. Maurer, Susan K Parsons, Jenica Upshaw, Jonathan W. Friedberg, Andrea Gallamini, Massimo Federico, Eliza A Hawkes, David Hodgson, Peter Johnson, Brian K. Link, Kerry J. Savage, Pier Luigi Zinzani, Andrew M Evens
Journal: Blood
Blood (2023) 142 (Supplement 1): 3067.
https://doi.org/10.1182/blood-2023-175079
Published: 2023
Journal Articles

Survival Patterns of Non-Randomized Patients in the IELSG37 Study: Deauville Score 4 Is Not Necessarily Associated with Poor Outcome in Primary Mediastinal Lymphoma

Emanuele Zucca, Luca Ceriani, Andrew S. Davies, Giovannino Ciccone, Umberto Ricardi, Alice Di Rocco, Iryna Kryachok, Barbara Botto, Monica Balzarotti, Alessandra Tucci, Vittorio Ruggero Zilioli, Sara Usai, Luca Arcaini, Elsa Pennese, Anna Dabrowska-Iwanicka, Andrés José María Ferreri, Franceso Merli, Wei Li Zhao, David Hodgson, Codruta Ionescu, Luigi Rigacci, Claudia Cellini, Caterina Stelitano, Stefano Volpetti, Carla Minoia, Michele Spina, Alexander Fossa, George Mikhaeel, Kate Cwynarski, Andrea Janikova, Yana Stepanishyna, Mats Jerkeman, Andreas Huettmann, Maria Gomes da Silva, Don A. Stevens, Sally F Barrington, Bogdan Małkowski, Ur Metser, Annibale Versari, Stephane Chauvie, Oreste Bagni, Kelly Cozens, Sonia Perticone, Nicoletta Ielmini, Letizia Deantonio, Jan Walewski, Marek Trneny, Mary Gospodarowicz, Franco Cavalli, Peter Johnson, Maurizio Martelli
Journal: Blood
Blood (2023) 142 (Supplement 1): 1718.
https://doi.org/10.1182/blood-2023-174093
Published: 2023
Journal Articles

Does R-IPI Remain Predictive of Relapse Risk for Patients with DLBCL Achieving a Complete Remission with Frontline Therapy: Landmark Analysis of Two Large Prospective Clinical Trials

Dima El-Sharkawi, Tasneem Elnafie, Sarah Thompson, Louise Stanton, Nicholas Counsell, Amit Sud, Ian Chau, Bhupinder Sharma, Peter Johnson, David C. Linch, Sunil Iyengar, Andrew Davies, David Cunningham
Journal: Blood
Blood (2022) 140 (Supplement 1): 7908–7909.
https://doi.org/10.1182/blood-2022-167852
Published: 2022
Journal Articles

Quality of Life Trajectories in Patients Treated with R-CHOP for Diffuse Large B-Cell Lymphoma As Part of the Remodl-B Trial (ISRCTN 51837425)

Joanna Hack, Inês Ralha, Sam Wilding, Louise Stanton, Josh Caddy, Sharon Barrans, Christoph Mamot, Urban Novak, Cathy Burton, Pamela McKay, Gavin Campbell, Andrew Davies, Peter Johnson
Journal: Blood
Blood (2022) 140 (Supplement 1): 6648–6649.
https://doi.org/10.1182/blood-2022-159442
Published: 2022
Journal Articles

Long Follow-up of the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma (RATHL) Trial (CRUK/07/033) Confirms the Safety of Both De-Escalation and Intensification of Chemotherapy

Stefano Luminari, Alexander Fosså, Judith Trotman, Daniel Molin, Francesco Annibale d'Amore, Gunilla Enblad, Leanne Berkahn, Sally F Barrington, John Radford, Massimo Federico, Amy A. Kirkwood, Peter Johnson
Journal: Blood
Blood (2022) 140 (Supplement 1): 766–767.
https://doi.org/10.1182/blood-2022-162780
Published: 2022
Journal Articles

Development and Validation of the a dvanced-Stage H odgkin Lymphoma (HL) I nternational P rognostication I ndex (A-HIPI): A Report from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium

Angie Mae Rodday, Susan K. Parsons, Jonathan W. Friedberg, Andrea Gallamini, Eliza Hawkes, David C. Hodgson, Peter Johnson, Brian K. Link, Eric Mou, Kerry J. Savage, Jenica Upshaw, Pier Luigi Zinzani, Matthew J. Maurer, Andrew M. Evens
Journal: Blood
Blood (2022) 140 (Supplement 1): 760–762.
https://doi.org/10.1182/blood-2022-164720
Published: 2022
Journal Articles

Durable Responses from Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase Ib/II Single Arm Study

Andrew J Davies, Josh Caddy, Katy McLaughlin, Christopher Wignall, Robert Waugh, Graham P. Collins, Louise Stanton, Geoff N Saunders, Thomas Cummin, Anna Schuh, Kirit M. Ardeshna, Andrew K. McMillan, John Radford, David John Lewis, Adam R Coleman, Gareth Griffiths, Cathy Burton, Sharon Barrans, Peter Johnson
Journal: Blood
Blood (2022) 140 (Supplement 1): 9478–9479.
https://doi.org/10.1182/blood-2022-163499
Published: 2022
Journal Articles

Five-Year Survival Results from the Remodl-B Trial (ISRCTN 51837425) Show Improved Outcomes in Diffuse Large B-Cell Lymphoma Molecular Subgroups from the Addition of Bortezomib to R-CHOP Chemoimmunotherapy

Andrew J Davies, Louise Stanton, Josh Caddy, Sharon Barrans, Sam Wilding, Geoff N Saunders, Christoph Mamot, Urban Novak, Andrew K. McMillan, Paul A Fields, Graham P. Collins, Richard Stephens, Francesco Cucco, Chulin Sha, Moniek Van Hoppe, Reuben M Tooze, Matthew A Care, Gareth Griffiths, Anna Schuh, Ming-Qing Du, David R Westhead, Cathy Burton, Peter Johnson
Journal: Blood
Blood (2022) 140 (Supplement 1): 1770–1772.
https://doi.org/10.1182/blood-2022-159976
Published: 2022
Journal Articles

Selinexor Enhances NK Cell Activation Against Lymphoma Cells Via Downregulation of HLA-E

Jack Fisher, Christopher J. Walker, Peter Johnson, Mark S Cragg, Francesco Forconi, Yosef Landesman, Salim I Khakoo, Matthew D Blunt
Journal: Blood
Blood (2021) 138 (Supplement 1): 2411.
https://doi.org/10.1182/blood-2021-144836
Published: 2021
Journal Articles

Characterising Tumour and Microenvironmental Responses to R-CHOP in Immunocompetent Mouse Models of DLBCL

Bernard D Maybury, Findlay Bewicke-Copley, Peter Johnson, Jude Fitzgibbon, Dinis Pedro Calado
Journal: Blood
Blood (2021) 138 (Supplement 1): 2401.
https://doi.org/10.1182/blood-2021-152318
Published: 2021
Journal Articles

Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Marginal Zone Lymphoma: Primary Analysis from a Phase 2 Study (CITADEL-204)

Tycel Phillips, Abraham Avigdor, Ronit Gurion, Caterina Patti, Paolo Corradini, Monica Tani, Amitkumar Mehta, Izidore S. Lossos, Pier Luigi Luigi Zinzani, Catherine Thieblemont, Wojciech Jurczak, Fred Zheng, Erica Rappold, Wanying Zhao, Peter Johnson
Journal: Blood
Blood (2021) 138 (Supplement 1): 44.
https://doi.org/10.1182/blood-2021-147778
Published: 2021
Journal Articles

KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas

James Heward, Lola Koniali, Annalisa D’Avola, Karina Close, Alison Yeomans, Martin Philpott, James Dunford, Tahrima Rahim, Ahad F. Al Seraihi, Jun Wang, Koorosh Korfi, Shamzah Araf, Sameena Iqbal, Findlay Bewicke-Copley, Emil Kumar, Darko Barisic, Maria Calaminici, Andrew Clear, John Gribben, Peter Johnson, Richard Neve, Pedro Cutillas, Jessica Okosun, Udo Oppermann, Ari Melnick, Graham Packham, Jude Fitzgibbon
Journal: Blood
Blood (2021) 138 (5): 370–381.
https://doi.org/10.1182/blood.2020008743
Published: 2021
Includes: Supplemental data
Journal Articles

Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma

Clinical Trials & Observations
Philippe Armand, Ann Janssens, Giuseppe Gritti, John Radford, John Timmerman, Antonio Pinto, Santiago Mercadal Vilchez, Peter Johnson, David Cunningham, John P. Leonard, Scott J. Rodig, Patricia Martín-Regueira, Anne Sumbul, Selda Samakoglu, Hao Tang, Stephen M. Ansell
Journal: Blood
Blood (2021) 137 (5): 637–645.
https://doi.org/10.1182/blood.2019004753
Published: 2021
Includes: Supplemental data
Journal Articles

Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)

Tycel J. Phillips, MD, Paolo Corradini, Ronit Gurion, MD, Caterina Patti, MD, Monica Tani, MD, Abraham Avigdor, MD, Wojciech Jurczak, MD PhD, Amitkumar Mehta, MD, Pier Luigi Zinzani, MD, Izidore S. Lossos, MD, Catherine Thieblemont, MD PhD, Fred Zheng, MD, Erica Rappold, Wanying Zhao, Peter Johnson, MD FRCP
Journal: Blood
Blood (2020) 136 (Supplement 1): 27–28.
https://doi.org/10.1182/blood-2020-134451
Published: 2020
Journal Articles

Subcutaneous Epcoritamab Induces Complete Responses with an Encouraging Safety Profile across Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Subtypes, Including Patients with Prior CAR-T Therapy: Updated Dose Escalation Data

Martin Hutchings, MD PhD, Rogier Mous, MD PhD, Michael Roost Clausen, MD PhD, Peter Johnson, MD FRCP, Kim M Linton, MBChB, PhD, Martine E.D. Chamuleau, MD PhD, David John Lewis, MD, Anna Sureda Balari, MD PhD, David Cunningham, MD FRCP, FMedSci, Roberto S Oliveri, MD PhD, Dena DeMarco, Brian Elliott, MD, Kuo-mei Chen, PhD, Pieternella J. Lugtenburg, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 45–46.
https://doi.org/10.1182/blood-2020-133820
Published: 2020